Pharmaceuticals News and Research

RSS

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

15 Apr 2010

Research report focuses on key influencers within employer health care market

Health Industries Research Companies' Employer & Coalition Service has released its spring 2010 market research. HIRC finds that employers are increasingly concerned about cancer medications and report sustained interest in health, wellness, and disease management initiatives.

15 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

Cegedim Dendrite announces global SaaS CRM agreement with UCB

Cegedim Dendrite, the world's leading provider of life-sciences specific Customer Relationship Solutions, has signed a global SaaS CRM agreement with biopharmaceutical company UCB.

15 Apr 2010

POZEN enters Settlement Agreement with Teva over generic Treximet ANDA patent infringement litigation

POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.

15 Apr 2010

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

FDA approves Sagent Pharmaceuticals' two ANDAs to market granisetron

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the Company's two abbreviated New Drug Applications to market granisetron hydrochloride injection, USP (granisetron), an antiemetic used to prevent nausea and vomiting caused by chemotherapy.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Patheon adds development and manufacturing softgel capability in Cincinnati facility

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it is adding development and manufacturing softgel capability in its Cincinnati facility, providing the pharmaceutical industry a new contract provider for this popular drug delivery system.

15 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Opinions divided on swine flu fear

According to health experts the swine flu pandemic is far from over and remains a threat to the population, especially the young. John Mackenzie, the Australian who heads the World Health Organization’s independent but secretive Emergency Committee said in a statement on Wednesday, “This is just as severe as we saw in 1957 and 1968, with one major difference. We are not seeing deaths in the elderly but we are seeing them in a more important group of the population, healthy young adults… It is much more severe than people tend to talk about.”

15 Apr 2010

Guardian examines Africa's health worker shortage

The Guardian's "Katine Chronicles" blog examines the global shortage of health workers. According to the U.K.'s Department for International Development (DfID), more than 50 countries have a "critical shortage" of health workers and Africa needs an additional 800,000 health workers by 2015.

15 Apr 2010

PSI acquires PEG-based technology

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its portfolio of drug delivery technologies through the acquisition of a versatile PEG-based technology. The technology covers a series of PEG-grafted cationic polymers that have a wide variety of applications in the pharmaceutical arena.

15 Apr 2010

Tel Aviv University is bioengineering tissues as an alternative to animal testing

It's illegal for health products with medical formulations to be accepted by the U.S. Food and Drug Administration without tests on animals ― a situation that has serious ethical and moral implications. New research in the field of tissue engineering by Prof. Amit Gefen of Tel Aviv University's Faculty of Engineering holds a promise that far fewer lab animals will be needed for the necessary experimental trials.

15 Apr 2010

FDA approves J&JPRD's PANCREAZE NDA

Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for PANCREAZE™ (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Exocrine pancreatic insufficiency is the inability to properly digest and absorb food due to a lack of enzymes made by the pancreas that are important in the digestion of fats, proteins, and sugars.

15 Apr 2010

AMRI announces multi-year research agreement with Navigen Pharmaceuticals

AMRI announced today that it has initiated a research collaboration with Navigen Pharmaceuticals, Inc. focused on the development of new drug therapies.

15 Apr 2010

Drug company payments to doctors: Continuing controversy

The New York Times has two stories on pharmaceutical industry payments to physicians and experts.

15 Apr 2010

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Building upon its powerful BD™ LSR cell analyzer platform, BD Biosciences launched today a new off-the-shelf BD LSRFortessa™ System, which uses up to four lasers -- blue, red, violet and UV -- that enable the detection of up to 18 colors simultaneously.

15 Apr 2010

Investment group acquires Arbor Pharmaceuticals

Arbor Pharmaceuticals, a specialty pharmaceutical company focused on pediatric medicine, announced today that an investment group led by Jason Wild of JW Asset Management, LLC and Edward Schutter has acquired the company.

15 Apr 2010

Pharmaceuticals News and Research

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Research report focuses on key influencers within employer health care market

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

Cegedim Dendrite announces global SaaS CRM agreement with UCB

POZEN enters Settlement Agreement with Teva over generic Treximet ANDA patent infringement litigation

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

FDA approves Sagent Pharmaceuticals' two ANDAs to market granisetron

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Patheon adds development and manufacturing softgel capability in Cincinnati facility

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

Opinions divided on swine flu fear

Guardian examines Africa's health worker shortage

PSI acquires PEG-based technology

Tel Aviv University is bioengineering tissues as an alternative to animal testing

FDA approves J&JPRD's PANCREAZE NDA

AMRI announces multi-year research agreement with Navigen Pharmaceuticals

Drug company payments to doctors: Continuing controversy

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Investment group acquires Arbor Pharmaceuticals

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence